Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 21 February, 2012 and appeared in  Public HealthIssue 614

BPA's Diabetes Link Strengthened by New Study

Growing evidence suggests that even minuscule amounts of BPA (used in everything from pesticides to water bottles) can scramble hormone signals, and trick fat cells into taking in more fat or mislead the pancreas into secreting excess insulin....

Advertisement

Among the most ubiquitous and scrutinized of these so-called endocrine disruptors is bisphenol, better known as BPA. The chemical is a common ingredient in plastics and food-can linings.

Angel Nadal, a BPA expert at the Miguel Hernandez University in Spain stated that, "When you eat something with BPA, it's like telling your organs that you are eating more than you are really eating."

Nadal's latest research, finds that the chemical triggers the release of almost double the insulin actually needed to break down food. High insulin levels can desensitize the body to the hormone over time, which in some people may then lead to weight gain and Type 2 diabetes.

To achieve this feat, BPA fools a receptor into thinking it is the natural hormone estrogen, an insulin regulator. Nadal's team found that even the tiniest amounts of BPA -- a quarter of a billionth of a gram -- did the trick. The effect disappeared when the researchers stripped the specific receptors from the study mice, evidence that they had in fact pinpointed BPA's chemical mechanism, which had previously eluded scientists. In laboratory tests of human cells, the response was even more pronounced.

"That pretty much nails it," Bruce Blumberg of the University of California, Irvine, who was not involved in the new study, told The Huffington Post. He notes that despite the prior associations made between BPA and metabolic problems, including obesity and diabetes, doubt had lingered because of a lack of understanding about how the phenomenon occurred. Long-term studies of children -- tracking BPA exposures and health outcomes -- remain ongoing around the world.

An estimated 90 percent of people in developed countries have BPA circulating in their blood at levels often higher than the threshold for causing hormone disruption used in Nadal's study. This high incidence is due not only to exposures from leaching food packages but also BPA-infused cash register receipts, dental sealants and toilet paper.

Frederick vom Saal, another expert in endocrine disruptors at the University of Missouri-Columbia stated that, "People are seeing effects of BPA down to 1000-fold below [Nadal's threshold]." "It takes so little of this chemical to cause harm."

Published in PLoS ONE, Feb 2012

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 21 February, 2012 and appeared in  Public HealthIssue 614

Past five issues: Diabetes Clinical Mastery Series Issue 202 | SGLT-2 Inhibitors Special Edition August 2014 | Issue 742 | Diabetes Clinical Mastery Series Issue 201 | Humulin Insulin Special Edition August 2014 |

2014 Most Popular Articles:

Low-carb Diet Recommended for Type 1 and 2 Diabetes Patients
Posted August 01, 2014
Statin Adherence Linked to New Onset Diabetes Risk
Posted July 25, 2014
New Combination of Diabetes Drugs Have Synergistic Effect
Posted August 08, 2014
New Encapsulated Beta-Cell Replacement Therapy for Type 1 Diabetes
Posted August 08, 2014
Regression from Prediabetes to Normal Glucose Reduces CVD Risk
Posted July 25, 2014
HbA1c Increases with Age
Posted August 01, 2014
Connection between Type 1 Diabetes and Ulcerative Colitis?
Posted August 01, 2014
Comparing Weekly Dulaglutide to Daily Liraglutide
Posted August 01, 2014
Transcutaneous Electrical Nerve Stimulator (TENS) for Pain Management
Posted July 25, 2014
HbA1c Variability and Mortality in Patients with Type 2 Diabetes
Posted July 18, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Do you recommend SGLT-2 drugs for type 1 diabetes?
CME/CE of the Week
Presented by CardioCareLive
Category: Cardiology



Search Articles On Diabetes In Control